Abstract
Preeclampsia is a multisystem disorder, pathophysiology of which is still not clear. It is one of the leading causes of maternal and fetal morbidity and mortality. Epigenetic programing is altered during fetal life and postnatal period and after birth, this sceniaro is changed to metabolic disorders of metabolic syndrome complex and this may contribute to future risk of hypertension, DM2, and cardiovascular disease. During (normal and abnormal) gestations, complex physiological changes occur in maternal blood. For studying next generation diagnostic biomarkers for maternal-fetal interface, it is essential to explore the protein changes in maternal serum during healthy gestation. Umbilical cord blood (UCB) is in contact with all the fetal tissues and can reflect both normal physiological as well as pathological states of the fetus. UCB can be compared with adult blood and the diagnostic potential of UCB still remains to be tapped. UCB will be a potential diagnostic medium in future in assessing infant health. Also, UCB can aid in detection and identification of candidate biomarkers for various disease pathways and it can be of help in assessing the existing or future adverse effects. Patents are available for biomarkers in preeclampsia and fewer patents are reported in UCB. Future studies will further uncover the diagnostic value of the umbilical cord blood in human physiology and pathology.
Keywords: Cord blood, diagnostic, markers preeclampsia, maternal, patents.
42